Leukemia

SuperGen Obtains FDA Approval To Market Anticancer Drug Daunorubicin

Published in Blood Weekly, December 20th, 2001

SuperGen, Inc., (SUPG) has received approval from the U.S. Food and Drug Administration (FDA) to market daunorubicin as a treatment for a variety of acute leukemias.

"We are pleased that the FDA has approved our application to market daunorubicin for acute leukemias," said Dr. Joseph Rubinfeld, chairman and chief executive officer of SuperGen. "The addition of daunorubicin further enhances our marketed portfolio, which contains Nipent and mitomycin. FDA approval once again demonstrates our ability to integrate all of our capabilities, from start to finish.

SuperGen's direct oncology sales force will be responsible for marketing daunorubicin to...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Blood Weekly

Source: Blood Weekly (2001-12-20)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry